Suppr超能文献

一项安慰剂对照试验,旨在评估雷贝拉唑与奥美拉唑连续8天给药对年轻健康男性受试者24小时胃内酸度和血浆胃泌素浓度的影响。

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.

作者信息

Williams M P, Sercombe J, Hamilton M I, Pounder R E

机构信息

University Department of Medicine, Royal Free and University College Medical School, London, UK.

出版信息

Aliment Pharmacol Ther. 1998 Nov;12(11):1079-89. doi: 10.1046/j.1365-2036.1998.00418.x.

Abstract

BACKGROUND

Rabeprazole (LY307640, E3810) is a new, potent, proton pump inhibitor. A single daily 20 mg dose significantly decreases 24-h intragastric acidity. There are no data currently available directly comparing the effect of rabeprazole on 24-h acidity with established proton pump inhibitors.

AIM

To compare the effects of rabeprazole 20 mg o.m. and omeprazole 20 mg o.m. on 24-h intragastric acidity and plasma gastrin concentration in a randomized, double-blind, placebo-controlled trial, in healthy H. pylori-negative subjects.

METHODS

Twenty-four healthy male volunteers, negative for H. pylori infection by serology and 13C-urea breath test, were studied on the 1st and 8th day of dosing with either placebo, rabeprazole 20 mg or omeprazole 20 mg, once each morning, in a crossover fashion. On days 1 and 8, hourly intragastric acidity was measured by gastric aspiration for 24 h from 08.00 hours. On day 8, plasma gastrin concentrations were also measured hourly from 08.00 to 24.00 hours, then every 2 h thereafter.

RESULTS

A single dose of both rabeprazole and omeprazole significantly decreased 24-h intragastric acidity compared with placebo. The 24-h acidity on day 1 was significantly decreased for rabeprazole compared with omeprazole (331 vs. 640 mmol.h/L, P < 0.001), resulting in a significantly higher median 24-h intragastric pH and longer times at which intragastric pH was > 3 and > 4. On day 8 of dosing, the decrease in 24-h intragastric acidity was greater with rabeprazole than with omeprazole, but the difference was not statistically significant (160 vs. 218 mmol.h/L, P = 0.1). However, 24-h plasma gastrin concentration (1687 vs. 1085 pmol.h/L. P < 0.01) and percentage time that intragastric pH was > 3 (69 vs. 59%, P = 0.008) and > 4 (60 vs. 51%, P = 0.03) were significantly greater.

CONCLUSIONS

Rabeprazole 20 mg once daily has a significantly faster onset of antisecretory activity than omeprazole 20 mg once daily. After 8 days the differences in intragastric pH > 3 and > 4 holding times persisted, but there was no significant difference in 24-h acidity.

摘要

背景

雷贝拉唑(LY307640,E3810)是一种新型强效质子泵抑制剂。每日单次服用20mg剂量可显著降低24小时胃内酸度。目前尚无直接比较雷贝拉唑与已上市质子泵抑制剂对24小时酸度影响的数据。

目的

在一项随机、双盲、安慰剂对照试验中,比较20mg口服雷贝拉唑和20mg口服奥美拉唑对健康幽门螺杆菌阴性受试者24小时胃内酸度和血浆胃泌素浓度的影响。

方法

24名经血清学和13C尿素呼气试验证实幽门螺杆菌感染阴性的健康男性志愿者,采用交叉设计,在给药的第1天和第8天,每天早晨分别服用安慰剂、20mg雷贝拉唑或20mg奥美拉唑。在第1天和第8天,从08:00开始通过胃抽吸每小时测量一次胃内酸度,持续24小时。在第8天,从08:00至24:00每小时测量一次血浆胃泌素浓度,之后每2小时测量一次。

结果

与安慰剂相比,单剂量雷贝拉唑和奥美拉唑均显著降低了24小时胃内酸度。与奥美拉唑相比,雷贝拉唑在第1天的24小时酸度显著降低(331 vs. 640 mmol·h/L,P < 0.001),导致24小时胃内pH中位数显著升高,胃内pH > 3和> 4的时间更长。在给药第8天,雷贝拉唑降低24小时胃内酸度的幅度大于奥美拉唑,但差异无统计学意义(160 vs. 218 mmol·h/L,P = 0.1)。然而,24小时血浆胃泌素浓度(1687 vs. 1085 pmol·h/L,P < 0.01)以及胃内pH > 3(69 vs. 59%,P = 0.008)和> 4(60 vs. 51%,P = 0.03)的时间百分比显著更高。

结论

每日一次服用20mg雷贝拉唑的抑酸活性起效速度明显快于每日一次服用20mg奥美拉唑。给药8天后,胃内pH > 3和> 4的持续时间差异仍然存在,但24小时酸度无显著差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验